Nigeria will receive its first shipment of Lenacapavir, a breakthrough HIV prevention injection, in March 2026.
The announcement has sparked fresh hope in the fight against HIV and AIDS. Moreover, health officials describe it as a major shift in the country’s prevention strategy.
For many Nigerians, this development comes as a surprise. However, authorities say preparations have already reached an advanced stage.
In a statement released on Monday, the National Agency for the Control of AIDS confirmed that groundwork is ongoing.
The agency said efforts are in motion to introduce the injectable drug under the national pre-exposure prophylaxis programme.
The Lenacapavir HIV prevention rollout is expected to transform how protection is delivered. Unlike daily oral PrEP, Lenacapavir is given as an injection twice a year. Clinical trials have shown that it can drastically reduce the risk of HIV transmission when properly used.
According to NACA, the move is a critical step toward ending the HIV epidemic in Nigeria. Furthermore, regulatory approval has already been secured from the National Agency for Food and Drug Administration and Control. This clearance clears a major path for importation and distribution.
Preparations have been described as careful and phased. Selected high-burden states will receive the first doses. In addition, assessments were conducted in 10 states, including Akwa Ibom, Anambra, Benue, Cross River, Ebonyi, the Federal Capital Territory, Gombe, Kano, Kwara and Lagos.
These reviews examined service capacity and identified gaps that must be fixed before deployment begins. Meanwhile, a national training-of-trainers programme has been completed in Abuja. Cascade training for frontline health workers has also started in the initial states.
Health providers are being prepared to administer the injection safely. They are also being trained to counsel patients effectively. Therefore, the rollout is expected to meet global standards.
Public awareness efforts are being intensified as well. Information materials have been developed to educate communities and encourage early acceptance. Moreover, demand creation campaigns will be launched ahead of the drug’s arrival.
The Lenacapavir HIV prevention rollout signals a new chapter in Nigeria’s public health journey. While daily pills have helped many people, adherence has remained a challenge. However, a twice-yearly injection could improve consistency and protection.
